MRD detection, personalized to every patient’s tumor. Wherever the signal starts, find it with RaDaR ST. Now covered by Medicare for (HR+) positive/HER2 negative breast cancer, HPV negative head and neck cancer, and immunotherapy.
One Order. Comprehensive Insights.
Confident Decisions.
Genomic and biomarker insights tailored to your patient for personalized therapy selection in one, streamlined order.
Our technology and test offerings are constantly evolving to offer state-of-the-art capabilities in cancer testing that align to the latest evidence and guidelines.
NeoGenomics provides unparalleled client support to help providers diagnose and choose the right therapy selection testing to address gaps in cancer care.
With over a decade of experience, NeoGenomics has contributed to a wealth of research, uncovering insights to advance breakthroughs in cancer diagnostics. Our expertise in real-world evidence (RWE) and genomic insights helps shape the future of precision medicine diagnostics.
